Imaging and Fluid Biomarkers of Disability Progression During 2 Years of Ocrelizumab Treatment in Black/African American and Hispanic/Latino People with Multiple Sclerosis (MS) in CHIMES

Authors
Category Primary study
ConferenceAnnual Meeting of the American Academy of Neurology, AAN 2025
Year 2025
This article has no abstract
Epistemonikos ID: 3caead814d0f6d26943dd4c72a8826d1389206ff
First added on: Sep 12, 2025